Physician profile
Michael J Stender
NPI 1114987047
$5,210.25
in general payments reported to CMS, 2019-2025
57 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $92.00 · 2021: $62.52 · 2022: $561 · 2023: $1,464 · 2024: $866 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,719 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,718.95 |
| Education | $226.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $574.33 | 2019-2025 | |
| Genentech USA, INC. | $529.86 | 2019-2025 | Tecentriq, Alecensa, Polivy |
| Pfizer INC. | $390.45 | 2019-2025 | |
| Genzyme Corporation | $278.74 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $241.84 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $196.82 | 2019-2025 | Lynparza, Enhertu, Tagrisso |
| Janssen Biotech, INC. | $190.29 | 2019-2025 | Rybrevant, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $165.68 | 2020-2025 | Datroway, Enhertu |
| Exelixis INC. | $142.36 | 2022-2025 | Cabometyx |
| Pharmaessentia USA Corporation | $138.78 | 2023 | Besremi |
| Astellas Pharma US INC | $138.67 | 2022-2025 | Xtandi, Vyloy, Xospata |
| Array Biopharma INC | $133.86 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Pharmacyclics LLC, An Abbvie Company | $126.51 | 2019-2023 | Imbruvica |
| Amgen INC. | $123.50 | 2021-2023 | Lumakras, Nplate, Vectibix |
| E.R. Squibb & Sons, L.L.C. | $113.98 | 2019-2025 | Opdivo |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $107.73 | 2019-2025 | Iclusig, Fruzaqla, Ninlaro |
| Abbvie INC. | $98.55 | 2019-2025 | |
| Adaptive Biotechnologies Corporation | $97.13 | 2025 | Clonoseq |
| Glaxosmithkline, LLC. | $66.69 | 2023-2025 | Ojjaara |
| Jazz Pharmaceuticals INC. | $63.57 | 2023 | |
| Aveo Pharmaceuticals, INC. | $59.90 | 2022-2025 | |
| Geron Corporation | $59.15 | 2025 | Rytelo |
| Gilead Sciences, INC. | $57.90 | 2019-2023 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $55.88 | 2023-2024 | Libtayo |
| Eisai INC. | $54.98 | 2023-2024 | |
| Celgene Corporation | $54.47 | 2023-2024 | Reblozyl, Pomalyst |
| Seagen INC. | $51.24 | 2022-2023 | Adcetris, Padcev |
| Medtronic, INC. | $50.52 | 2023 | Ligasure |
| Bayer Healthcare Pharmaceuticals INC. | $49.33 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $46.90 | 2025 | Ultomiris |
| Genmab U.S., INC. | $46.82 | 2023-2025 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $41.54 | 2024-2025 | Onivyde, Somatuline Depot |
| Sumitomo Pharma America, INC. | $39.85 | 2023-2024 | Orgovyx |
| Sobi, INC | $39.23 | 2022-2025 | |
| Deciphera Pharmaceuticals INC. | $37.71 | 2025 | Qinlock |
| Beigene USA, INC. | $36.45 | 2020-2022 | |
| Emd Serono, INC. | $36.11 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $35.65 | 2025 | Enjaymo |
| Kite Pharma, INC. | $33.27 | 2020-2023 | |
| Tersera Therapeutics LLC | $32.60 | 2025 | Zoladex |
| Emmaus Medical, INC. | $32.17 | 2023 | Endari |
| Servier Pharmaceuticals LLC | $29.99 | 2023 | |
| Tesaro, INC. | $28.10 | 2019 | |
| Blueprint Medicines Corporation | $26.68 | 2023 | Ayvakit |
| Ethicon INC. | $25.60 | 2025 | Monarch Platform |
| Kyowa Kirin, INC. | $23.38 | 2025 | |
| Mirati Therapeutics, INC. | $22.63 | 2024 | Krazati |
| Agios Pharmaceuticals, INC. | $22.12 | 2021 | |
| Lilly USA, LLC | $21.77 | 2025 | Verzenio, Jaypirca |
| Beone Medicines USA, INC. | $21.12 | 2025 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $20.90 | 2023 | Odomzo |
| G1 Therapeutics, INC. | $18.65 | 2023 | Cosela |
| Rigel Pharmaceuticals, INC. | $17.31 | 2023 | Tavalisse, Rezlidhia |
| Tempus Ai, INC | $17.20 | 2024 | |
| Puma Biotechnology, INC. | $16.29 | 2023 | |
| Morphosys, US INC. | $16.23 | 2023 | Monjuvi |
| Amag Pharmaceuticals, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.